Arvid R.
- Country
- Norway
- Department
- Age Related Medicine
Research Overview
- Phase IIa Multicenter RCT on Ambroxol Efficacy in Prodromal and Mild Dementia with Lewy Bodies
- Randomized, Double-Blind, Placebo-Controlled 12-Month Study of Fasudil Hydrochloride in Patients with Early Alzheimer's Disease
- Phase 1B Dose Range Study of (-)-Phenserine Tartrate vs. Donepezil Hydrochloride in Early or Mild Alzheimer's Disease and Mild Cognitive Impairment
Data & Insights
Has run more than one trial at 7 of 7 partner sites.
Specializations
Neurodegenerative Disorders
The investigator specializes in the treatment of Dementia with Lewy Bodies (DLB), conducting innovative therapeutic research in cognitive and neuropsychiatric outcomes for patients in prodromal and mild stages of the condition.
- Early-stage DLB intervention
- Cognitive function assessment
- Neuropsychiatric symptom management
Their work encompasses functional outcomes and therapeutic approaches for patients newly diagnosed with DLB.
Cognitive Disorders
The investigator focuses on early and mild Alzheimer's disease and Mild Cognitive Impairment (MCI), exploring novel therapeutic compounds and comparing their efficacy with established treatments.
- Early-stage cognitive decline
- Biomarker analysis
- Comparative treatment efficacy
Their research emphasizes early intervention strategies and biomarker-based approaches in cognitive disorders.
Memory Preservation
The investigator's work centers on preventive approaches for memory loss in early Alzheimer's disease, investigating therapeutic interventions for cognitive preservation.
- Memory function preservation
- Early-stage interventions
- Long-term therapeutic outcomes
Their research involves extended duration studies to evaluate therapeutic effectiveness in memory preservation.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.